Skip to main content

Table 2 ALK-positive histiocytosis with CNS involvement reported in the literature

From: Multisystem ALK-positive histiocytosis: a multi-case study and literature review

Authors

Gender

Age

Orangs involved

Gene fusion

Treatment

Follow-up

1. Chang, et al. [2]

M

2 y 9 mo

CNS, Intestine, hematopoietic system

ALK-FISH + 

Steroids and chemotherapy (ECICM)

DOD (2 mo)

2. Qiu et al. [12]

M

49 y

CNS, bone, soft tissue, visceral organs, pleura

KIF5B-ALK

Gamma knife, chemotherapy, and ALK inhibitor

SD (7 mo)

3. Kashima et al. [5]

F

16 y

CNS, breast, pancreas, and lungs

KIF5B-ALK

Surgical resection followed by inhibitor

NED (44 mo)

4. Rossi et al. [17, 19]

M

10 mo

CNS, lung, liver, soft tissue

KIF5B-ALK

Surgical resection followed by chemotherapy (vinblastine/prednisone), combined with ALK inhibitor

NED (13 mo)

Kemps et al. [19]

      

5.

F

2 y

CNS, bone, lung, liver, skin, soft tissue, kidney, breast, pancreas, LN

KIF5B-ALK

Chemotherapy (vinblastine/prednisone) followed by ALK inhibitor

ARD (21 mo)

6.

F

10 y

CNS, bone, lung, cervix, thyroid, submandibular salivary gland, LN

KIF5B-ALK

ALK inhibitor

NED (2 y)

7.

F

19 y

CNS/PNS, bone, lung, liver, breast, pancreas, LN

KIF5B-ALK

Chemotherapy (cladribine), followed by ALK inhibitor

ARD (2 y)

8.

F

28 y

CNS/PNS, bone

KIF5B-ALK

ALK inhibitor

ARD (9 mo)

9.

F

41 y

CNS, bone, lung, skin, soft tissue, LN

KIF5B-ALK

Interferon-a followed by ALK inhibitor

ARD (6 y)

Lucas et al. [9]

      

10.

F

7 y

CNS

KIF5B-ALK

Surgical resection

NED (1 y)

11.

F

10 y

CNS

KIF5B-ALK

Surgical resection

NED (6 mo)

12. Rossi et al. [17, 19]

F

11 y

CNS

KIF5B-ALK

Surgical resection

NED (9 mo)

Kemps et al. [19]

      

13.

F

7 mo

CNS

KIF5B-ALK

Corticosteroids, followed by ALK inhibitor

ARD (5 mo)

14.

F

9 mo

CNS

ALK-FISH + 

N/A

LTF

15.

M

2.5 y

CNS

KIF5B-ALK

Chemotherapy followed by ALK inhibitor

NED (16 mo)

16.

F

3 y

CNS

KIF5B-ALK

Corticosteroids, followed by surgical resection

NED (12 mo)

17.

F

7 y

CNS

KIF5B-ALK

Chemotherapy (clofarabine)

NED (6 mo)

18.

F

13 y

CNS/PNS

KIF5B-ALK

Surgical resection followed by ALK inhibitor

ARD (2.5 y)

19.

M

20 y

CNS

KIF5B-ALK

Surgical resection

NED (10 mo)

Current

      

20.

F

51 y

CNS, lung, LN

KIF5B-ALK

Surgical resection followed by ALK inhibitor

ARD (24 mo)

21.

M

17 mo

Brain, lung, liver, skin

KIF5B-ALK

Surgical resection followed by chemoradiotherapy and ALK inhibitor

DOD (8 mo)

  1. ARD Alive with regressive disease; CNS Central nervous system; DOD Died of disease; ECICM Etoposide, cyclosporine, immunoglobulins, cytarabine, methotrexate; F Female; LN Lymph node; LTF Lost to follow-up; M Male; mo, Month; NED No evidence of disease; PNS Peripheral nervous system; SD Stable disease; y Year